Loading...
Docoh

Blueprint Medicines (BPMC)

Utility
Inhibitors of RET
22 Mar 22
Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
Jason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro
Filed: 29 Jan 20
Utility
RET inhibitor for use in treating cancer having a RET alteration
15 Mar 22
Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily.
Erica Evans Raab, Beni B. Wolf
Filed: 18 Dec 20
Utility
PRKC fusions
1 Mar 22
The invention provides PRKC gene fusions, PRKC fusion proteins, and fragments of those genes and polypeptides.
Nicolas Stransky, Joseph L. Kim
Filed: 16 Jul 19
Utility
Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
1 Feb 22
Jason D. Brubaker, Paul E. Fleming, Joseph L. Kim, Brett Williams, Brian L. Hodous
Filed: 18 Oct 18
Utility
Compounds and compositions useful for treating disorders related to NTRK
13 Jul 21
This invention relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants.
Steven Mark Wenglowsky, Chandrasekhar V. Miduturu, Neil Bifulco, Joseph L. Kim
Filed: 31 Jul 19
Utility
Compounds and compositions useful for treating disorders related to NTRK
29 Jun 21
Steven Mark Wenglowsky, Natasja Brooijmans, Chandrasekhar V. Miduturu, Neil Bifulco, Jr.
Filed: 3 Jul 18
Utility
Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
22 Jun 21
Compounds and compositions useful for treating disorders related to KIT and PDGFR are described herein.
Brian L. Hodous, Joseph L. Kim, Kevin J. Wilson
Filed: 29 Mar 18
Utility
Inhibitors of the fibroblast growth factor receptor
28 Dec 20
Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
Neil Bifulco, Jr., Lucian V. DiPietro, Brian L. Hodous, Chandrasekhar V. Miduturu
Filed: 18 Feb 19
Utility
PIK3C2G fusions
28 Dec 20
The invention provides to PIK3C2G (phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma) gene fusions and PIK3C2G fusion proteins.
Nicolas Stransky, Ethan G. Cerami, Joseph L. Kim, Christoph Lengauer
Filed: 29 Jul 14
Utility
Compositions and methods for treating KIT- and PDGFRA-mediated diseases
9 Nov 20
Thomas A. Dineen
Filed: 7 Apr 20
Utility
Compositions useful for treating disorders related to kit
19 Oct 20
Compounds and compositions useful for treating disorders related to mutant KIT are described herein.
Kevin J. Wilson
Filed: 6 May 18
Utility
2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
14 Sep 20
Natasja Brooijmans, Lucian V. DiPietro, Paul E. Fleming, Joseph L. Kim, Steven Mark Wenglowsky, Yulian Zhang
Filed: 19 Dec 18
Utility
Inhibitors of activin receptor-like kinase
1 Jun 20
Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
Kevin J. Wilson, Josh Waetzig
Filed: 4 Mar 19
Utility
PIK3CA fusions
1 Jun 20
The invention provides PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) gene fusions, and fragments of those gene fusions.
Ethan G. Cerami, Christoph Lengauer, Nicolas Stransky
Filed: 26 Feb 19
Utility
Inhibitors of RET
9 Mar 20
Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
Jason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro
Filed: 19 Jul 18
  • 1
Patents are sorted by USPTO publication date, most recent first